ArticleInfection and immunity2014
Mycoplasma pneumoniae modulates STAT3-STAT6/EGFR-FOXA2 signaling to induce overexpression of airway mucins.
Article in Infection and immunity, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed.
- Innate and adaptive immunity pathways linking Mycoplasma pneumoniae to pediatric asthma phenotypes.European journal of pediatrics · 2026Review
- The cell with many faces: lung macrophage plasticity and function in response to environmental and pathogenic insults.Physiological reviews · 2026Review
- Attenuated efficacy of Streptococcus salivarius K12 against Mycoplasma pneumoniae infection in mice.BMC microbiology · 2026Article
- Integrative Traditional Chinese Medicine Strategies for Refractory Mycoplasma Pneumonia in Children: Clinical Challenges, Mechanisms, and Evidence-Based Insights.Infection and drug resistance · 2026Review
- The FOXA transcription factors in allergic airway disease and asthma.Frontiers in allergy · 2026Review
- Clinical features and risk factors of plastic bronchitis in Mycoplasma pneumoniae pneumonia children with pulmonary consolidation: a prospective cohort study.Frontiers in pediatrics · 2026Article
- Research progress on the mechanisms of mucus retention after mycoplasma pneumoniae infection.Frontiers in cellular and infection microbiology · 2026Review
- Levels of Toll-Like Receptor 2, Myeloid Differentiation Primary Response 88 and Mucin 5AC, Oligomeric Mucus/Gel-Forming in Bronchoalveolar Lavage Fluid for Predicting SevereInfection and drug resistance · 2026Article
- Immunopathogenesis, molecular phenotyping, and host-directed interventions for severe pediatricFrontiers in cellular and infection microbiology · 2026Review
- Immune dysregulation inFrontiers in immunology · 2026Review
- Clinical characteristics and predictor analysis of pediatric Mycoplasma pneumoniae pneumonia with small segment molded sputum plugs: a retrospective study.Italian journal of pediatrics · 2025Article
- The predictive value of MUC5AC levels in the sputum of children withMicrobiology spectrum · 2025Article
- The Immune Modulatory Role of Surfactants inJournal of inflammation research · 2025Review
- Establishment of a Mouse Model ofMicroorganisms · 2024Article
- In vitro modelling of bacterial pneumonia: a comparative analysis of widely applied complex cell culture models.FEMS microbiology reviews · 2024Review
- Distinct lower respiratory tract microbiota profiles linked to airway mucus hypersecretion in children withFrontiers in microbiology · 2024Article
- Airway Basal Stem Cells in COVID-19 Exhibit a Proinflammatory Signature and Impaired Mucocililary Differentiation.American journal of respiratory cell and molecular biology · 2024Article
- Insights into the defensive roles of lncRNAs duringFrontiers in microbiology · 2024Review
- Respiratory microbiota imbalance in children with Mycoplasma pneumoniae pneumonia.Emerging microbes & infections · 2023Article
- miRNA, lncRNA and circRNA: targeted molecules with therapeutic promises in Mycoplasma pneumoniae infection.Archives of microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Aberrant mucin secretion and accumulation in the airway lumen are clinical hallmarks associated with various lung diseases such as asthma, chronic obstructive pulmonary disease, and cystic fibrosis. Mycoplasma pneumoniae, long appreciated as one of the triggers of acute exacerbations of chronic pulmonary diseases, has recently been reported to promote excessive mucus secretion. However, the mechanism of mucin overproduction induced by M. pneumoniae remains unclear. This study aimed to determine the mechanism by which M. pneumoniae induces mucus hypersecretion by using M. pneumoniae infection of mouse lungs, human primary bronchial epithelial (NHBE) cells cultured at the air-liquid interface, and the conventionally cultured airway epithelial NCI-H292 cell line. We demonstrated that M. pneumoniae induced the expression of mucins MUC5AC and MUC5B by activating the STAT6-STAT3 and epidermal growth factor receptor (EGFR) signal pathways, which in turn downregulated FOXA2, a transcriptional repressor of mucin biosynthesis. The upstream stimuli of these pathways, including interleukin-4 (IL-4), IL-6, and IL-13, increased dramatically upon exposure to M. pneumoniae. Inhibition of the STAT6, STAT3, and EGFR signaling pathways significantly restored the expression of FOXA2 and attenuated the expression of airway mucins MUC5AC and MUC5B. Collectively, these studies demonstrated that M. pneumoniae induces airway mucus hypersecretion by modulating the STAT/EGFR-FOXA2 signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.